International Guillain-Barré Syndrome Outcome Study

protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

the IGOS Consortium

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

Original languageEnglish (US)
Pages (from-to)68-76
Number of pages9
JournalJournal of the Peripheral Nervous System
Volume22
Issue number2
DOIs
StatePublished - Jun 1 2017

Fingerprint

Observational Studies
Cohort Studies
Outcome Assessment (Health Care)
Polyradiculoneuropathy
Electrophysiology
Information Systems
Multicenter Studies
Cerebrospinal Fluid
Epidemiology
Therapeutics
Demography
Antibodies
DNA
Infection
Serum
Research

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Neurology

Cite this

@article{1fb35d8ad7da4dbf963f5a5be45f1601,
title = "International Guillain-Barr{\'e} Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barr{\'e} syndrome",
abstract = "Guillain-Barr{\'e} syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.",
author = "{the IGOS Consortium} and Jacobs, {Bart C.} and {van den Berg}, Bianca and Christine Verboon and Govindsinh Chavada and Cornblath, {David R.} and Gorson, {Kenneth C.} and Thomas Harbo and Hartung, {Hans Peter} and Hughes, {Richard A.C.} and Susumu Kusunoki and {van Doorn}, {Pieter A.} and Willison, {Hugh J.} and Jacobs, {B. C.} and Hughes, {R. A.C.} and Cornblath, {D. R.} and Gorson, {K. C.} and Hartung, {H. P.} and S. Kusunoki and {van Doorn}, {P. A.} and Willison, {H. J.} and {van Woerkom}, M. and {van den Berg}, B. and C. Verboon and J. Roodbol and Jacobs, {B. C.} and Reisin, {R. C.} and Reddel, {S. W.} and Z. Islam and B. Islam and Mohammad, {Q. D.} and {van den Bergh}, P. and Feasby, {T. E.} and Wang, {Y. Z.} and T. Harbo and Y. P{\'e}r{\'e}on and Hartung, {H. P.} and Lehmann, {H. C.} and E. Dardiotis and E. Nobile-Orazio and S. Kusunoki and N. Shahrizaila and Jacobs, {B. C.} and {van den Berg}, B. and C. Verboon and K. Bateman and I. Illa and Querol, {L. A.} and Hsieh, {S. T.} and Willison, {H. J.} and Tulio Bertorini",
year = "2017",
month = "6",
day = "1",
doi = "10.1111/jns.12209",
language = "English (US)",
volume = "22",
pages = "68--76",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - International Guillain-Barré Syndrome Outcome Study

T2 - protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

AU - the IGOS Consortium

AU - Jacobs, Bart C.

AU - van den Berg, Bianca

AU - Verboon, Christine

AU - Chavada, Govindsinh

AU - Cornblath, David R.

AU - Gorson, Kenneth C.

AU - Harbo, Thomas

AU - Hartung, Hans Peter

AU - Hughes, Richard A.C.

AU - Kusunoki, Susumu

AU - van Doorn, Pieter A.

AU - Willison, Hugh J.

AU - Jacobs, B. C.

AU - Hughes, R. A.C.

AU - Cornblath, D. R.

AU - Gorson, K. C.

AU - Hartung, H. P.

AU - Kusunoki, S.

AU - van Doorn, P. A.

AU - Willison, H. J.

AU - van Woerkom, M.

AU - van den Berg, B.

AU - Verboon, C.

AU - Roodbol, J.

AU - Jacobs, B. C.

AU - Reisin, R. C.

AU - Reddel, S. W.

AU - Islam, Z.

AU - Islam, B.

AU - Mohammad, Q. D.

AU - van den Bergh, P.

AU - Feasby, T. E.

AU - Wang, Y. Z.

AU - Harbo, T.

AU - Péréon, Y.

AU - Hartung, H. P.

AU - Lehmann, H. C.

AU - Dardiotis, E.

AU - Nobile-Orazio, E.

AU - Kusunoki, S.

AU - Shahrizaila, N.

AU - Jacobs, B. C.

AU - van den Berg, B.

AU - Verboon, C.

AU - Bateman, K.

AU - Illa, I.

AU - Querol, L. A.

AU - Hsieh, S. T.

AU - Willison, H. J.

AU - Bertorini, Tulio

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

AB - Guillain-Barré syndrome (GBS) is an acute polyradiculoneuropathy with a highly variable clinical presentation, course, and outcome. The factors that determine the clinical variation of GBS are poorly understood which complicates the care and treatment of individual patients. The protocol of the ongoing International GBS Outcome Study (IGOS), a prospective, observational, multicenter cohort study that aims to identify the clinical and biological determinants and predictors of disease onset, subtype, course and outcome of GBS is presented here. Patients fulfilling the diagnostic criteria for GBS, regardless of age, disease severity, variant forms, or treatment, can participate if included within 2 weeks after onset of weakness. Information about demography, preceding infections, clinical features, diagnostic findings, treatment, course, and outcome is collected. In addition, cerebrospinal fluid and serial blood samples for serum and DNA is collected at standard time points. The original aim was to include at least 1,000 patients with a follow-up of 1–3 years. Data are collected via a web-based data entry system and stored anonymously. IGOS started in May 2012 and by January 2017 included more than 1,400 participants from 143 active centers in 19 countries across 5 continents. The IGOS data/biobank is available for research projects conducted by expertise groups focusing on specific topics including epidemiology, diagnostic criteria, clinimetrics, electrophysiology, antecedent events, antibodies, genetics, prognostic modeling, treatment effects, and long-term outcome of GBS. The IGOS will help to standardize the international collection of data and biosamples for future research of GBS.

UR - http://www.scopus.com/inward/record.url?scp=85020274741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020274741&partnerID=8YFLogxK

U2 - 10.1111/jns.12209

DO - 10.1111/jns.12209

M3 - Article

VL - 22

SP - 68

EP - 76

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 2

ER -